- Home
- DKI vs GTBP Comparison
DKI vs GTBP Comparison
Compare DKI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKI | GTBP |
|---|---|---|
| Founded | 2018 | 1965 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | DKI | GTBP |
|---|---|---|
| Price | $5.91 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 184.9K | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.26 |
| 52 Week High | $11.80 | $3.73 |
Technical Indicators
Market Signals| Indicator | DKI | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 61.11 |
| Support Level | $4.82 | $0.39 |
| Resistance Level | $6.80 | $0.79 |
| Average True Range (ATR) | 0.80 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 57.21 | 95.46 |
Price Performance
Historical ComparisonAbout DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.